Angion Biomedica initiates BB3 Stage II trial in coronary attack Angion Biomedica Corp.

We are optimistic about Angion’s approach. Initiating this heart attack trial is an extremely important milestone for Angion, stated Itzhak D. Goldberg, M.D., F.A.C.R., CEO of Angion Biomedica. This exciting study will provide key insights as to whether the encouraging data we generated in preclinical models shall translate to patient benefit. .. Angion Biomedica initiates BB3 Stage II trial in coronary attack Angion Biomedica Corp.Rates of meningococcal disease continued to be at historic lows.S. There have been no human-to-human being transmissions. However, cases continue to exceed those reported through the 1990s and early 2000s.2 million illnesses each year in the U.S. The largest multistate outbreak in 2013 was traced to contaminated poultry. Other notable outbreaks were associated with live poultry, tahini sesame paste, cucumbers, and small pet turtles.9 % to 2,138 cases in 2013.